0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      The Impact of Early Lens Opacity Progression on Visual Acuity and Refraction

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The purpose of the present study was to evaluate the change in visual acuity and refraction taking place in eyes with progressing early lens opacities. Four hundred and ten hypercholesterolemic men in Eastern Finland who participated in the Kuopio Atherosclerosis Prevention Study were followed up for 3 years. Lens opacities were graded using the lens opacity classification system II (LOCS II). The change of visual acuity and refractive error from baseline to a 36-month examination was compared for different types of lens opacities. During the 3-year period, progression in the LOCS II was observed in 9.2% of the eyes for nuclear, in 4.8% for cortical and in 0.5% of the eyes for posterior subcapsular opacities. Increasing nuclear sclerosis reduced visual acuity statistically significantly both with and without correction. Hypermetropization was seen to continue in eyes with no lens opacity progression. Myopization was more common in eyes with lens opacity progression, although this was not statistically significant.

          Related collections

          Author and article information

          Journal
          OPH
          Ophthalmologica
          10.1159/issn.0030-3755
          Ophthalmologica
          S. Karger AG
          0030-3755
          1423-0267
          1997
          1997
          01 April 2010
          : 211
          : 4
          : 242-246
          Affiliations
          aDepartment of Ophthalmology and bResearch Institute of Public Health, University of Kuopio, Finland
          Article
          310799 Ophthalmologica 1997;211:242–246
          10.1159/000310799
          9216016
          © 1997 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Original Paper

          Comments

          Comment on this article